The most commonly stated statistic about clinical trials is that for every one drug on the market, there are nine that failed. A look back through 2018 indicates there were a great many successes, but plenty of challenges as well. Here’s a look at 10 notable drug challenges of the year.

Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat.